Skip to main content

Home/ Cancer/ Group items tagged study PCA

Rss Feed Group items tagged

Matti Narkia

Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependen... - 0 views

  •  
    Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.
    Mantena SK, Sharma SD, Katiyar SK.
    Mol Cancer Ther. 2006 Feb;5(2):296-308.
    PMID: 16505103
    doi: 10.1158/1535-7163.MCT-05-0448

    The effectiveness of berberine in checking the growth of androgen-insensitive, as well as androgen-sensitive, prostate cancer cells without affecting the growth of normal prostate epithelial cells indicates that it may be a promising candidate for prostate cancer therapy.

    The evaluation of ancient herbal medicines may indicate novel strategies for the treatment of prostate cancer, which remains the leading cause of cancer-related deaths in American men (1). In our present investigation, we show that a naturally occurring isoquinoline alkaloid, berberine, significantly inhibits the proliferation and reduces the viability of DU145 and PC-3 as well as LNCaP cells (Fig. 1), which suggests that berberine may be an effective chemotherapeutic agent against both androgen-sensitive and androgen-insensitive prostate cancer cells. Importantly, we found that berberine did not exhibit toxicity to nonneoplastic human prostate epithelial cells under the conditions used, except for a moderate reduction in cell viability at higher concentrations when cells were treated in vitro for an extended period of time.

    In conclusion, the results of the present study indicate that berberine inhibits proliferation and induces G1-phase arrest and apoptosis in human prostate cancer cells but not in normal human prostate epithelial cells. In addition, we provide mechanistic evidence that berberine-induced apoptosis in prostate carcinoma cells, particularly hormone-refractory prostate carcinoma cells, is mediated through enhanced expression of Bax, disruption of the mitochondrial membrane potential, and activation of caspase-3.
Matti Narkia

Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids - Journal... - 0 views

  •  
    Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids.
    Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A, Edwards IJ, D'Agostino R, Zhang H, Wu H, Kang JX, Chen YQ.
    J Clin Invest. 2007 Jul;117(7):1866-75.
    PMID: 17607361

    Our data suggest that modulation of prostate cancer development by polyunsaturated fatty acids is mediated in part through Bad-dependent apoptosis. This study highlights the importance of gene-diet interactions in prostate cancer.
Matti Narkia

The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of th... - 0 views

  •  
    The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.
    Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J.
    Anticancer Res. 2009 Sep;29(9):3511-36. Review.
    PMID: 19667145

    CONCLUSION: Significant associations with VDR polymorphisms have been reported in cancer of the breast (Fok1, Bsm1, Taq1, Apa1, poly (A)), prostate (Fok1, Bsm1, Taq1, poly (A)), skin (Fok1, Bsm1, A-1210), colorectum (Fok1, Bsm1), ovary (Fok1, Apa1) and bladder (Fok1), and in renal cell carcinoma (Taq1, Apa1). However, conflicting data have been reported for most malignancies. After careful evaluation of the actual literature, it can be summarized that data indicating an association of VDR polymorphisms and cancer risk are strongest for breast cancer (Bsm1, Fok1), prostate cancer (Fok1) and malignant melanoma (MM) (Fok1). Data indicating an association of VDR polymorphisms and cancer prognosis are strongest for prostate cancer (Fok1), breast cancer (Bsm1, Taq1), MM (Bsm1) and renal cell carcinoma (Taq1).
Matti Narkia

A multicountry ecologic study of risk and risk reduction factors for prostate cancer mo... - 0 views

  •  
    A multicountry ecologic study of risk and risk reduction factors for prostate cancer mortality.
    Grant WB.
    Eur Urol. 2004 Mar;45(3):271-9.
    PMID: 15036670

    CONCLUSIONS: These results are consistent with insulin-like growth factor-I (IGF-I), being an important risk factor for prostate cancer, with alcohol and calcium being less important risk factors, and with allium family vegetables, and, to a lesser extent, vitamin D being important risk reduction factors. These results should provide guidance for additional studies on dietary and environmental links to prostate cancer.
Matti Narkia

Vitamin D and the epidemiology of prostate cancer. - Semin Dial. 2005 Jul-Aug;18(4):276... - 0 views

  •  
    Vitamin D and the epidemiology of prostate cancer.
    Schwartz GG.
    Semin Dial. 2005 Jul-Aug;18(4):276-89. Review.
    PMID: 16076349
    DOI: 10.1111/j.1525-139X.2005.18403.x
Matti Narkia

Association between serum 25(OH)D and death from prostate cancer - British Journal of C... - 0 views

  •  
    Association between serum 25(OH)D and death from prostate cancer.
    Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE.
    Br J Cancer. 2009 Feb 10;100(3):450-4. Epub 2009 Jan 20.
    PMID: 19156140
    doi:10.1038/sj.bjc.6604865

    The serum level of 25(OH)D may be involved in disease progression and is a potential marker of prognosis in patients with prostate cancer.
Matti Narkia

Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse... - 0 views

  •  
    Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
    Woo TC, Choo R, Jamieson M, Chander S, Vieth R.
    Nutr Cancer. 2005;51(1):32-6.
    PMID: 15749627
Matti Narkia

White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic p... - 0 views

  •  
    White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice.
    Adams LS, Phung S, Wu X, Ki L, Chen S.
    Nutr Cancer. 2008;60(6):744-56.
    PMID: 19005974
Matti Narkia

Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within th... - 0 views

  •  
    Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Argüelles MV, Sánchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ.
    Am J Epidemiol. 2009 Apr 9. [Epub ahead of print]
    PMID: 19359375
    doi:10.1093/aje/kwp022
Matti Narkia

White Button Mushroom (Agaricus Bisporus) Exhibits Antiproliferative and Proapoptotic P... - 0 views

  •  
    White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice.
    Adams LS, Phung S, Wu X, Ki L, Chen S.
    Nutr Cancer. 2008;60(6):744-56.
    PMID: 19005974
    DOI: 10.1080/01635580802192866
Matti Narkia

Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy - 0 views

  •  
    Vitamin D and intervention trials in prostate cancer: from theory to therapy.
    Schwartz GG.
    Ann Epidemiol. 2009 Feb;19(2):96-102. Epub 2008 Jul 10.
    PMID: 18619854
    doi:10.1016/j.annepidem.2008.03.007

    This suggests that whereas vitamin D (e.g., cholecalciferol) might prevent prostate cancer, existing prostate tumors likely would require treatment with 1,25(OH)(2)D and/or its analogs. The major obstacle to the use of 1,25(OH)(2)D in patients therapeutically is the risk of hypercalcemia. Several maneuvers to reduce this risk, including pulse dosing and the use of less calcemic 1,25(OH)(2)D analogs, have been explored in Phase I-III clinical trials. Once merely a promise, vitamin D-based therapies for prostate cancer may soon be medical practice.
Matti Narkia

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependen... - 0 views

  •  
    CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Ang JE, Olmos D, de Bono JS.
    Br J Cancer. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17.
    PMID: 19223900
    doi:10.1038/sj.bjc.6604904
Matti Narkia

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms... - 0 views

  •  
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
    Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.
    J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21.
    PMID: 18645193
    DOI: 10.1200/JCO.2007.15.9749
Matti Narkia

Vitamin D and cancer Ali MM, Vaidya V - J Can Res Ther 2007 Oct-Dec - 0 views

  •  
    Vitamin D and cancer.
    Ali MM, Vaidya V.
    J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30. Review.
    PMID: 18270398
    DOI: 10.4103/0973-1482.38998
Matti Narkia

Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in d... - 0 views

  •  
    Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy.
    Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, McHugh K.
    Neoplasia. 2006 Feb;8(2):112-24.
    PMID: 16611404
Matti Narkia

A 22-y prospective study of fish intake in relation to prostate cancer incidence and mo... - 0 views

  •  
    A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality.
    Chavarro JE, Stampfer MJ, Hall MN, Sesso HD, Ma J.
    Am J Clin Nutr. 2008 Nov;88(5):1297-303.
    PMID: 18996866

    Conclusion: These results suggest that fish intake is unrelated to prostate cancer incidence but may improve prostate cancer survival.

Matti Narkia

Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostat... - 0 views

  •  
    Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk.
    Fradet V, Cheng I, Casey G, Witte JS.
    Clin Cancer Res. 2009 Mar 24. [Epub ahead of print]
    PMID: 19318492
    DOI: 10.1158/1078-0432.CCR-08-2503
Matti Narkia

Apoptotic effects of dietary and synthetic sphingolipids in androgen-independent (PC-3)... - 0 views

  •  
    Apoptotic effects of dietary and synthetic sphingolipids in androgen-independent (PC-3) prostate cancer cells.
    Kent KD, Clubbs EA, Harper WJ, Bomser JA.
    Lipids. 2008 Feb;43(2):143-9. Epub 2008 Jan 10.
    PMID: 18188632
    DOI: 10.1007/s11745-007-3148-
Matti Narkia

White button mushroom (Agaricus bisporus) exhibits...[Nutr Cancer. 2008] - PubMed Result - 0 views

  •  
    White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice.
    Adams LS, Phung S, Wu X, Ki L, Chen S.
    Nutr Cancer. 2008;60(6):744-56.
    PMID: 19005974
Matti Narkia

Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC)... - 0 views

  •  
    Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.
    Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G.
    Eur Urol. 2005 Apr;47(4):449-54; discussion 454-5. Epub 2005 Jan 19.
    PMID: 15774240
    doi:10.1016/j.eururo.2004.12.001
1 - 20 of 32 Next ›
Showing 20 items per page